Parnell Pharmaceuticals Holdings Ltd (PARNF)
- Previous Close
0.0000 - Open
0.0000 - Bid --
- Ask --
- Day's Range
0.0000 - 0.0000 - 52 Week Range
0.0000 - 0.0200 - Volume
1,600 - Avg. Volume
0 - Market Cap (intraday)
28,670 - Beta (5Y Monthly) 19.68
- PE Ratio (TTM)
∞ - EPS (TTM)
0.0000 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Parnell Pharmaceuticals Holdings Ltd, a commercial-stage pharmaceutical company, focuses on developing, manufacturing, and marketing animal pharmaceutical products worldwide. The company operates through four segments: Companion Animal, Production Animal - U.S., Production Animal - Rest of World, and Manufacturing Operations. It markets various products, including estroPLAN and GONAbreed reproductive hormone products for enhancing cattle breeding performance; Zydax for the treatment of osteoarthritis (OA) in dogs and horses; and Glyde, a nutraceutical product for the treatment of OA, as well as Parnell PROcept, which adds an additional injection of estroPLAN after the first injection. The company also offers mySYNCH, a digital tool to help veterinarians and producers optimize reproduction and maximize economic gains. Parnell Pharmaceuticals Holdings Ltd was incorporated in 2009 and is headquartered in Alexandria, Australia.
www.parnell.com--
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: PARNF
Performance Overview: PARNF
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PARNF
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PARNF
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
0.90
Enterprise Value/EBITDA
2.39
Financial Highlights
Profitability and Income Statement
Profit Margin
-4.16%
Return on Assets (ttm)
6.47%
Return on Equity (ttm)
--
Revenue (ttm)
34.17M
Net Income Avi to Common (ttm)
-1.42M
Diluted EPS (ttm)
0.0000
Balance Sheet and Cash Flow
Total Cash (mrq)
3.68M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-1.06M
Research Analysis: PARNF
Company Insights: PARNF
PARNF does not have Company Insights